Literature DB >> 34665389

Hyperammonemia in Inherited Metabolic Diseases.

Graziela Schmitt Ribas1,2, Franciele Fátima Lopes3, Marion Deon3, Carmen Regla Vargas4,5.   

Abstract

Ammonia is a neurotoxic compound which is detoxified through liver enzymes from urea cycle. Several inherited or acquired conditions can elevate ammonia concentrations in blood, causing severe damage to the central nervous system due to the toxic effects exerted by ammonia on the astrocytes. Therefore, hyperammonemic patients present potentially life-threatening neuropsychiatric symptoms, whose severity is related with the hyperammonemia magnitude and duration, as well as the brain maturation stage. Inherited metabolic diseases caused by enzymatic defects that compromise directly or indirectly the urea cycle activity are the main cause of hyperammonemia in the neonatal period. These diseases are mainly represented by the congenital defects of urea cycle, classical organic acidurias, and the defects of mitochondrial fatty acids oxidation, with hyperammonemia being more severe and frequent in the first two groups mentioned. An effective and rapid treatment of hyperammonemia is crucial to prevent irreversible neurological damage and it depends on the understanding of the pathophysiology of the diseases, as well as of the available therapeutic approaches. In this review, the mechanisms underlying the hyperammonemia and neurological dysfunction in urea cycle disorders, organic acidurias, and fatty acids oxidation defects, as well as the therapeutic strategies for the ammonia control will be discussed.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Ammonia; Defects of fatty acids oxidation; Hyperammonemia; Organic acidurias; Urea cycle disorders

Mesh:

Substances:

Year:  2021        PMID: 34665389     DOI: 10.1007/s10571-021-01156-6

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   4.231


  179 in total

1.  N-acetylglutamate synthetase (NAGS) deficiency: diagnosis, clinical observations and treatment.

Authors:  C Bachmann; J P Colombo; K Jaggi
Journal:  Adv Exp Med Biol       Date:  1982       Impact factor: 2.622

Review 2.  Glutamine: a Trojan horse in ammonia neurotoxicity.

Authors:  Jan Albrecht; Michael D Norenberg
Journal:  Hepatology       Date:  2006-10       Impact factor: 17.425

Review 3.  Hyperammonemia in review: pathophysiology, diagnosis, and treatment.

Authors:  Ari Auron; Patrick D Brophy
Journal:  Pediatr Nephrol       Date:  2011-03-23       Impact factor: 3.714

4.  Ammonia does not selectively block IPSPs in rat hippocampal pyramidal cells.

Authors:  B E Alger; R A Nicoll
Journal:  J Neurophysiol       Date:  1983-06       Impact factor: 2.714

Review 5.  Ammonia toxicity to the brain and creatine.

Authors:  Claude Bachmann; Olivier Braissant; Anne-Marie Villard; Olivier Boulat; Hugues Henry
Journal:  Mol Genet Metab       Date:  2004-04       Impact factor: 4.797

6.  Long-term outcome of patients with urea cycle disorders and the question of neonatal screening.

Authors:  Claude Bachmann
Journal:  Eur J Pediatr       Date:  2003-11-21       Impact factor: 3.183

7.  Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study.

Authors:  Subrat Kumar Acharya; Vikram Bhatia; Vishnubhatla Sreenivas; Shankar Khanal; Subrat Kumar Panda
Journal:  Gastroenterology       Date:  2009-06       Impact factor: 22.682

8.  Adeno-associated viral gene therapy corrects a mouse model of argininosuccinic aciduria.

Authors:  Scott N Ashley; Jayme M L Nordin; Elizabeth L Buza; Jenny A Greig; James M Wilson
Journal:  Mol Genet Metab       Date:  2018-08-28       Impact factor: 4.797

9.  Clinical and biochemical outcomes of patients with medium-chain acyl-CoA dehydrogenase deficiency.

Authors:  Daniela R Anderson; Krista Viau; Lorenzo D Botto; Marzia Pasquali; Nicola Longo
Journal:  Mol Genet Metab       Date:  2019-11-25       Impact factor: 4.797

10.  N-acetylglutamate synthase deficiency: an insight into the genetics, epidemiology, pathophysiology, and treatment.

Authors:  Nicholas Ah Mew; Ljubica Caldovic
Journal:  Appl Clin Genet       Date:  2011-08-24
View more
  2 in total

Review 1.  Mitochondrial hepatopathy: Anticipated difficulties in management of fatty acid oxidation defects and urea cycle defects.

Authors:  Aathira Ravindranath; Moinak Sen Sarma
Journal:  World J Hepatol       Date:  2022-01-27

2.  Case report: Is exchange transfusion a possible treatment for metabolic decompensation in neonates with methylmalonic aciduria in the setting of limited resources?

Authors:  Xiaoyu Cui; Na Li; Hong Xue; Fang Zhang; Jianbo Shu; Yang Liu
Journal:  Front Pediatr       Date:  2022-07-25       Impact factor: 3.569

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.